Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

No studies have performed direct pairwise comparisons of the effectiveness and safety of
warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background Effectiveness data on novel oral anticoagulants (NOACs) versus warfarin for
stroke prevention in non-valvular atrial fibrillation (NVAF) by prior warfarin use are limited …

Background and Purpose—Limited real-world data exist comparing each non–vitamin K
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background No studies have directly compared the effectiveness and safety of dabigatran
and rivaroxaban using US Medicare data. Objective Our objective was to compare …